Base de dados : MEDLINE
Pesquisa : D02.540.576.500.992.250 [Categoria DeCS]
Referências encontradas : 126 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 13 ir para página                         

  1 / 126 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24412560
[Au] Autor:Lu X; Tian Y; Lian X; Jin Y; Jin T; Zhao Q; Hu B; Shen X; Fan X
[Ad] Endereço:Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
[Ti] Título:Integrated systems toxicology approaches identified the possible involvement of ABC transporters pathway in erythromycin estolate-induced liver injury in rat.
[So] Source:Food Chem Toxicol;65:343-55, 2014 Mar.
[Is] ISSN:1873-6351
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Erythromycin estolate (EE), a macrolide antibiotic, has caused hepatotoxicity both in human and experimental animals. The objective of this study was to integrate general toxicology, transcriptomics, and metabonomics approaches to determine the mechanisms of EE-induced liver injury. Histopathological examinations unveiled dose-dependent hydropicdegenerationof hepatocytes after EE administration. Further biochemical analysis of treated rats confirmed that cholestasis and oxidative stress were induced by EE treatments. Microarray analysis of the livers from EE-treated rats showed that differentially expressed genes were enriched in the ABC transporters, cell cycle, and p53 signaling pathways. Metabonomics analysis revealed that EE exposure could lead to disturbances in energy metabolism, amino acid metabolism, lipid metabolism, and nucleotide metabolism, which may be attributable to EE toxicological effects on the liver through oxidative stress. 5-Oxoproline may be used as a biomarker of EE-induced liver injury. More importantly, the integrated analysis of transcriptomics and metabonomics datasets demonstrated that the induction of ABC transporters pathway severed as an anti-cholestatic adaptive mechanism in EE-induced cholestasis. In addition, EE-induced liver injury was also related to alteration in glycogen and sucrose metabolism, arachidonic acid metabolism, and linoleic acid metabolism pathways.
[Mh] Termos MeSH primário: Transportadores de Cassetes de Ligação de ATP/metabolismo
Estolato de Eritromicina/toxicidade
Fígado/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Relação Dose-Resposta a Droga
Perfilação da Expressão Gênica
Fígado/metabolismo
Masculino
Análise de Sequência com Séries de Oligonucleotídeos
Ratos
Ratos Wistar
Reação em Cadeia da Polimerase em Tempo Real
Reação em Cadeia da Polimerase Via Transcriptase Reversa
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
XRJ2P631HP (Erythromycin Estolate)
[Em] Mês de entrada:1410
[Cu] Atualização por classe:140214
[Lr] Data última revisão:
140214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140114
[St] Status:MEDLINE


  2 / 126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:21901685
[Au] Autor:Raynes Greenow CH; Roberts CL; Bell JC; Peat B; Gilbert GL; Parker S
[Ad] Endereço:School of Public Health, University of Sydney, Rm 125, Edward Ford Building A27, Sydney, New South Wales, Australia, 2006.
[Ti] Título:Antibiotics for ureaplasma in the vagina in pregnancy.
[So] Source:Cochrane Database Syst Rev;(9):CD003767, 2011 Sep 07.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Preterm birth is a significant perinatal problem contributing to perinatal morbidity and mortality. Heavy vaginal ureaplasma colonisation is suspected of playing a role in preterm birth and preterm rupture of the membranes. Antibiotics are used to treat infections and have been used to treat pregnant women with preterm prelabour rupture of the membranes, resulting in some short-term improvements. However, the benefit of using antibiotics in early pregnancy to treat heavy vaginal colonisation is unclear. OBJECTIVES: To assess whether antibiotic treatment of pregnant women with heavy vaginal ureaplasma colonisation reduces the incidence of preterm birth and other adverse pregnancy outcomes. SEARCH STRATEGY: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 May 2011). SELECTION CRITERIA: Randomised controlled trials comparing any antibiotic regimen with placebo or no treatment in pregnant women with ureaplasma detected in the vagina. DATA COLLECTION AND ANALYSIS: Three review authors independently assessed eligibility and trial quality and extracted data. MAIN RESULTS: We included one trial, involving 1071 women. Of these, 644 women between 22 weeks and 32 weeks' gestation were randomly assigned to one of three groups of antibiotic treatment (n = 174 erythromycin estolate, n = 224 erythromycin stearate, and n = 246 clindamycin hydrochloride) or a placebo (n = 427). Preterm birth data was not reported in this trial. Incidence of low birthweight less than 2500 grams was only evaluated for erythromycin (combined, n = 398) compared to placebo (n = 427) and there was no statistically significant difference between the two groups (risk ratio (RR) 0.70, 95% confidence interval (CI) 0.46 to 1.07). There were no statistically significant differences in side effects sufficient to stop treatment between either group (RR 1.25, 95% CI 0.85 to 1.85). AUTHORS' CONCLUSIONS: There is insufficient evidence to assess whether pregnant women who have vaginal colonisation with ureaplasma should be treated with antibiotics to prevent preterm birth.Preterm birth is a significant perinatal problem. Upper genital tract infections, including ureaplasmas, are suspected of playing a role in preterm birth and preterm rupture of the membranes. Antibiotics are used to treat women with preterm prelabour rupture of the membranes; this may result in prolongation of pregnancy and lowers the risks of maternal and neonatal infection. However, antibiotics may be beneficial earlier in pregnancy to eradicate potentially causative agents.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Complicações Infecciosas na Gravidez/tratamento farmacológico
Infecções por Ureaplasma/tratamento farmacológico
Doenças Vaginais/tratamento farmacológico
[Mh] Termos MeSH secundário: Clindamicina/uso terapêutico
Eritromicina/análogos & derivados
Eritromicina/uso terapêutico
Estolato de Eritromicina/uso terapêutico
Feminino
Seres Humanos
Gravidez
Complicações Infecciosas na Gravidez/microbiologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Doenças Vaginais/microbiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 3U02EL437C (Clindamycin); 63937KV33D (Erythromycin); LXW024X05M (erythromycin stearate); XRJ2P631HP (Erythromycin Estolate)
[Em] Mês de entrada:1110
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110909
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD003767.pub3


  3 / 126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19000270
[Au] Autor:Albarellos GA; Kreil VE; Ambros LA; Waxman S; Montoya L; Tarragona L; Quaine PC; Hallu RE; Rebuelto M
[Ad] Endereço:Cátedra de Farmacología, Facultad de Ciencias Veterinarias, Universidad de Buenos Aires, Buenos Aires, Argentina. albarell@fvet.uba.ar
[Ti] Título:Pharmacokinetics of erythromycin after the administration of intravenous and various oral dosage forms to dogs.
[So] Source:J Vet Pharmacol Ther;31(6):496-500, 2008 Dec.
[Is] ISSN:1365-2885
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The purpose of this study was to describe and compare the pharmacokinetic properties of different formulations of erythromycin in dogs. Erythromycin was administered as lactobionate (10 mg/kg, IV), estolate tablets (25 mg/kg p.o.) and ethylsuccinate tablets or suspension (20 mg/kg p.o.). After intravenous (i.v.) administration, the principal pharmacokinetic parameters were (mean +/- SD): AUC((0-infinity)) 4.20 +/- 1.66 microg x h/mL; C(max) 6.64 +/- 1.38 microg/mL; V(z) 4.80 +/- 0.91 L/kg; Cl(t) 2.64 +/- 0.84 L/h.kg; t((1/2)lambda) 1.35 +/- 0.40 h and MRT 1.50 +/- 0.47 h. After the administration of estolate tablets and ethylsuccinate suspension, the principal pharmacokinetic parameters were (mean +/- SD): C(max), 0.30 +/- 0.17 and 0.17 +/- 0.09 microg/mL; t(max), 1.75 +/- 0.76 and 0.69 +/- 0.30 h; t((1/2)lambda), 2.92 +/- 0.79 and 1.53 +/- 1.28 h and MRT, 5.10 +/- 1.12 and 2.56 +/- 1.77 h, respectively. The administration of erythromycin ethylsuccinate tablets did not produce measurable serum concentrations. Only the i.v. administration rendered serum concentrations above MIC(90) = 0.5 microg/mL for 2 h. However, these results should be cautiously interpreted as tissue erythromycin concentrations have not been measured in this study and, it is recognized that they can reach much higher concentrations than in blood, correlating better with clinical efficacy.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Antibacterianos/farmacocinética
Estolato de Eritromicina/administração & dosagem
Estolato de Eritromicina/farmacocinética
Etilsuccinato de Eritromicina/farmacocinética
[Mh] Termos MeSH secundário: Administração Oral
Animais
Antibacterianos/sangue
Área Sob a Curva
Estudos Cross-Over
Cães
Formas de Dosagem
Estolato de Eritromicina/sangue
Etilsuccinato de Eritromicina/administração & dosagem
Etilsuccinato de Eritromicina/sangue
Feminino
Meia-Vida
Injeções Intravenosas
Modelos Lineares
Masculino
Taxa de Depuração Metabólica
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Dosage Forms); 1014KSJ86F (Erythromycin Ethylsuccinate); XRJ2P631HP (Erythromycin Estolate)
[Em] Mês de entrada:0902
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:081113
[St] Status:MEDLINE
[do] DOI:10.1111/j.1365-2885.2008.00982.x


  4 / 126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:17636756
[Au] Autor:Altunaiji S; Kukuruzovic R; Curtis N; Massie J
[Ad] Endereço:Zayed Military Hospital, Paedatrics Department, PO Box 12898, Aldhaid, Sharjah, United Arab Emirates. altunaiji1@gmail.com
[Ti] Título:Antibiotics for whooping cough (pertussis).
[So] Source:Cochrane Database Syst Rev;(3):CD004404, 2007 Jul 18.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Whooping cough is a highly contagious disease. Infants are at highest risk of severe disease and death. Erythromycin for 14 days is currently recommended for treatment and contact prophylaxis, but is of uncertain benefit. OBJECTIVES: To study the benefits and risks of antibiotic treatment of and contact prophylaxis against whooping cough. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), the Database of Abstracts of Reviews of Effects (DARE) (The Cochrane Library Issue 1, 2007); MEDLINE (January 1966 to March 2007); EMBASE (January 1974 to March 2007). SELECTION CRITERIA: All randomised and quasi-randomised controlled trials of antibiotics for treatment of, and contact prophylaxis against, whooping cough. DATA COLLECTION AND ANALYSIS: Three to four review authors independently extracted data and assessed the quality of each trial. MAIN RESULTS: Thirteen trials with 2197 participants met the inclusion criteria: 11 trials investigated treatment regimens; 2 investigated prophylaxis regimens. The quality of the trials was variable.Short-term antibiotics (azithromycin for three to five days, or clarithromycin or erythromycin for seven days) were as effective as long-term (erythromycin for 10 to 14 days) in eradicating Bordetella pertussis (B. pertussis) from the nasopharynx (relative risk (RR) 1.02, 95% confidence interval (CI) 0.98 to 1.05), but had fewer side effects (RR 0.66, 95% CI 0.52 to 0.83). Trimethoprim/sulfamethoxazole for seven days was also effective. Nor were there differences in clinical outcomes or microbiological relapse between short and long-term antibiotics. Contact prophylaxis of contacts older than six months of age with antibiotics did not significantly improve clinical symptoms or the number of cases developing culture-positive B. pertussis. AUTHORS' CONCLUSIONS: Although antibiotics were effective in eliminating B. pertussis, they did not alter the subsequent clinical course of the illness. There is insufficient evidence to determine the benefit of prophylactic treatment of pertussis contacts.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Coqueluche/tratamento farmacológico
Coqueluche/prevenção & controle
[Mh] Termos MeSH secundário: Azitromicina/uso terapêutico
Bordetella pertussis
Claritromicina/uso terapêutico
Busca de Comunicante
Eritromicina/uso terapêutico
Estolato de Eritromicina/uso terapêutico
Etilsuccinato de Eritromicina/uso terapêutico
Seres Humanos
Lactente
Ensaios Clínicos Controlados Aleatórios como Assunto
Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
Coqueluche/transmissão
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 1014KSJ86F (Erythromycin Ethylsuccinate); 63937KV33D (Erythromycin); 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination); 83905-01-5 (Azithromycin); H1250JIK0A (Clarithromycin); XRJ2P631HP (Erythromycin Estolate)
[Em] Mês de entrada:0710
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:070720
[St] Status:MEDLINE


  5 / 126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:16187483
[Au] Autor:Murugan P; Pari L
[Ad] Endereço:Department of Biochemistry, Faculty of Science, Annamalai University, Annamalai Nagar - 608 002, Tamil Nadu, India.
[Ti] Título:Effect of tetrahydrocurcumin on erythromycin estolate-induced lipid peroxidation in rats.
[So] Source:J Basic Clin Physiol Pharmacol;16(1):1-15, 2005.
[Is] ISSN:0792-6855
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Erythromycin estolate (EME), a potent macrolide antibiotic, generates free radicals, but their role in the development of liver toxicity is not yet well understood. The present study was carried out to investigate the effect of the antioxidant drug tetrahydrocurcumin (a metabolite of curcumin, the main component of turmeric) against EME-induced lipid peroxidation in rats. The oral administration of combined THC (80 mg/kg body weight) and EME (800 mg/kg body weight) for 15 days significantly decreased lipid peroxidation and enhanced cellular antioxidant defenses when compared with the group treated with EME alone. Supplemental histopathological examination of liver sections revealed that THC had a better antioxidant effect than Silymarin (200 mg/kg body weight), a reference drug. The results of this study indicate that THC affords significant protection against EME-induced lipid peroxidation.
[Mh] Termos MeSH primário: Anticarcinógenos/farmacologia
Curcumina/análogos & derivados
Estolato de Eritromicina/antagonistas & inibidores
Estolato de Eritromicina/toxicidade
Peroxidação de Lipídeos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Antioxidantes/metabolismo
Catalase/metabolismo
Curcumina/farmacologia
Feminino
Glutationa/metabolismo
Glutationa Peroxidase/metabolismo
Glutationa Transferase/metabolismo
Peróxido de Hidrogênio/metabolismo
Rim/efeitos dos fármacos
Rim/metabolismo
Rim/patologia
Fígado/efeitos dos fármacos
Fígado/metabolismo
Fígado/patologia
Oxidantes/metabolismo
Ratos
Ratos Wistar
Superóxido Dismutase/metabolismo
Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticarcinogenic Agents); 0 (Antioxidants); 0 (Oxidants); 0 (Thiobarbituric Acid Reactive Substances); 00U0645U03 (tetrahydrocurcumin); BBX060AN9V (Hydrogen Peroxide); EC 1.11.1.6 (Catalase); EC 1.11.1.9 (Glutathione Peroxidase); EC 1.15.1.1 (Superoxide Dismutase); EC 2.5.1.18 (Glutathione Transferase); GAN16C9B8O (Glutathione); IT942ZTH98 (Curcumin); XRJ2P631HP (Erythromycin Estolate)
[Em] Mês de entrada:0510
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050929
[St] Status:MEDLINE


  6 / 126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:15674946
[Au] Autor:Altunaiji S; Kukuruzovic R; Curtis N; Massie J
[Ad] Endereço:Zayed Military Hospital, Zayed Street, PO Box 3740, Abu Dhabi, United Arab Emirates. saltunaiji@hotmail.com
[Ti] Título:Antibiotics for whooping cough (pertussis).
[So] Source:Cochrane Database Syst Rev;(1):CD004404, 2005 Jan 25.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Whooping cough is a highly contagious disease. Infants are the population at highest risk of severe disease and death. Erythromycin for 14 days is recommended for treatment and contact prophylaxis but this regime is considered inconvenient and prolonged. The value of contact prophylaxis is uncertain. OBJECTIVES: To study the benefits and risks of antibiotic treatment of and contact prophylaxis against whooping cough. SEARCH STRATEGY: The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2004); MEDLINE (January 1966 to February 2004); EMBASE (January 1974 to August 2003); conference abstracts and reference lists of articles were searched. Study investigators and pharmaceutical companies were approached for additional information (published or unpublished studies). There were no constraints based on language or publication status. SELECTION CRITERIA: All randomised and quasi-randomised controlled trials of antibiotics for treatment of and contact prophylaxis against whooping cough were included in the systematic review. DATA COLLECTION AND ANALYSIS: At least three reviewers independently extracted data and assessed the quality of each trial. MAIN RESULTS: Twelve trials with 1,720 participants met the inclusion criteria. Ten trials investigated treatment regimens and two investigated prophylaxis regimens. The quality of the trials was variable. Results showed that short-term antibiotics (azithromycin for three days, clarithromycin for seven days, or erythromycin estolate for seven days) were equally effective with long-term antibiotic treatment (erythromycin estolate or erythromycin for 14 days) in the microbiological eradication of Bordetella pertussis (B. pertussis) from the nasopharynx. The relative risk (RR) was 1.02 (95% confidence interval (CI) 0.98 to 1.05). Side effects were fewer with short-term treatment (RR 0.66; 95% CI 0.52 to 0.83). There were no differences in clinical improvement or microbiological relapse between short and long-term treatment regimens. Contact prophylaxis (of contacts older than six months of age) with antibiotics did not significantly improve clinical symptoms or the number of cases that developed culture positive B. pertussis. AUTHORS' CONCLUSIONS: Antibiotics are effective in eliminating B. pertussis from patients with the disease, rendering them non-infectious, but do not alter the subsequent clinical course of the illness. Effective regimens include: three days of azithromycin, seven days of clarithromycin, seven or 14 days of erythromycin estolate, and 14 days of erythromycin ethylsuccinate. Considering microbiological clearance and side effects, three days of azithromycin or seven days of clarithromycin are the best regimens. Seven days of trimethoprim/sulfamethoxazole also appeared to be effective for the eradication of B. pertussis from the nasopharynx and may serve as an alternative antibiotic treatment for patients who cannot tolerate a macrolide. There is insufficient evidence to determine the benefit of prophylactic treatment of pertussis contacts.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Coqueluche/tratamento farmacológico
Coqueluche/prevenção & controle
[Mh] Termos MeSH secundário: Azitromicina/uso terapêutico
Bordetella pertussis
Claritromicina/uso terapêutico
Busca de Comunicante
Eritromicina/uso terapêutico
Estolato de Eritromicina/uso terapêutico
Etilsuccinato de Eritromicina/uso terapêutico
Seres Humanos
Lactente
Ensaios Clínicos Controlados Aleatórios como Assunto
Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
Coqueluche/transmissão
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 1014KSJ86F (Erythromycin Ethylsuccinate); 63937KV33D (Erythromycin); 8064-90-2 (Trimethoprim, Sulfamethoxazole Drug Combination); 83905-01-5 (Azithromycin); H1250JIK0A (Clarithromycin); XRJ2P631HP (Erythromycin Estolate)
[Em] Mês de entrada:0505
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050128
[St] Status:MEDLINE


  7 / 126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15231980
[Au] Autor:Langley JM; Halperin SA; Boucher FD; Smith B; Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC)
[Ad] Endereço:Clinical Trials Research Center, IWK Health Centre, Dalhousie University, Halifax, Canada. joanne.langley@dal.ca
[Ti] Título:Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis.
[So] Source:Pediatrics;114(1):e96-101, 2004 Jul.
[Is] ISSN:1098-4275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Although universal immunization against Bordetella pertussis (whooping cough) infection has resulted in dramatic reductions in the incidence of pertussis, outbreaks continue to occur in countries with excellent vaccine coverage. Treatment of infection may ameliorate symptom severity during the catarrhal phase of pertussis but has no effect on established paroxysms, emesis, or apnea if given during the paroxysmal or convalescent phases. Erythromycin, recommended for treatment of pertussis to prevent transmission of infection, is poorly tolerated because of gastrointestinal side effects. We compared the safety and efficacy of erythromycin with azithromycin for treatment of pertussis in a large, randomized, controlled trial that enrolled children from primary care practices in 1 American and 11 Canadian urban centers. METHODS: Children who were 6 months to 16 years of age and had cough illness that was suspected to be or was culture confirmed as pertussis were randomized to azithromycin (10 mg/kg on day 1 and 5 mg/kg on days 2-5 as a single dose) or erythromycin estolate (40 mg/kg/day in 3 divided doses for 10 days) with stratification by center. The primary outcome measure was bacteriologic cure of infection as determined by cultures of nasopharyngeal aspirates. Culture-positive participants had a second aspirate collected at the end of therapy (days 5-7 for azithromycin, days 10-12 for erythromycin) and 1 week after therapy. Bacteriologic cure was defined as negative cultures at the end of therapy. Bacteriologic relapse was defined as a positive culture 1 week after completion of therapy and after a negative end-of-therapy culture. Secondary outcomes were pertussis diagnosed by serology and polymerase chain reaction (PCR), treatment-associated adverse events, compliance, and presence of clinical symptoms at the end of the treatment course. Serology was performed using standard enzyme-linked immunosorbent assay methods. A participant was considered to have pertussis when the PCR was positive or a 4-fold increase in pertussis toxin antibody between baseline and follow-up visits was observed. PCR was performed using a 1046-bp ClaI DNA fragment from B pertussis. Adverse events (nausea, vomiting, diarrhea, any gastrointestinal complaint, or other) were determined by a parent-completed diary that was reviewed with study personnel during study visits. Compliance was measured by review of the parent medication diary during study visits and observation of medication containers by the pharmacist at study completion. Symptoms were determined by history collected by study personnel at enrollment and subsequently from the diary. The design of the study was an equivalence trial, aimed at demonstrating that the bacteriologic failure rates with the 2 therapies did not differ by >8%. For the safety analysis, all participants who received at least 1 dose of study drug were included. In the per-protocol efficacy analysis, all culture-positive participants with end-of-treatment cultures were considered. RESULTS: A total of 477 children were enrolled and randomly assigned to either azithromycin (n = 239) or erythromycin (n = 238). Of these children, 114 (24%) grew B pertussis from nasopharyngeal specimens (azithromycin group: 58 of 239 [24%]; erythromycin group: 56 of 238 [23%]); these children composed the efficacy cohort for the per-protocol and intention-to-treat analyses. Serology and PCR added 52 children to the number considered to have pertussis for a total of 35% (166 of 477) of all children who presented with cough illness. In the safety analysis (antibiotic side effects, compliance) and comparison of cough symptoms after treatment, all randomized children are reported in their assigned treatment group. At end of therapy, bacterial eradication was demonstrated in all 53 patients in the azithromycin group and all 53 patients in the erythromycin group with follow-up cultures available (eradication 100%; 95% confidence interval [CI]: 93.3-100). No bacterial recurrence was demonstrated in children with 1 week posttreatment nasopharyngeal cultures available (51 and 53 participants in the azithromycin and erythromycin arms, respectively [0%, 95% CI: 0-7.0; and 0%, 95% CI: 0-6.7]). No serious adverse events attributable to study drug were observed. Gastrointestinal adverse events were reported less frequently in azithromycin (18.8%; 45 of 239) than in erythromycin estolate (41.2%; 98 of 238) recipients (90% CI on difference: -29.0% to -15.7%) as a result of less nausea (2.9% vs 8.4%; 95% CI: -8.9% to -2.0%), less vomiting (5.0% vs 13.0%; 95% CI: -4.9% to -1.4%), and less diarrhea (7.1% vs 11.8%; 95% CI: -9.0% to -0.3%). Children who were randomized to azithromycin were much more likely to have complied with antimicrobial therapy over the treatment period. In the azithromycin group, 90% of children took 100% of prescribed doses, whereas only 55% of children in the erythromycin group took 100% of prescribed doses. CONCLUSIONS: In this large, multicenter, randomized trial, we found that azithromycin is as effective as erythromycin estolate for the treatment of pertussis in children. Gastrointestinal adverse events were much more common with erythromycin treatment than azithromycin. Compliance with therapy was markedly better with azithromycin than with erythromycin in this study.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Azitromicina/uso terapêutico
Estolato de Eritromicina/uso terapêutico
Coqueluche/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Antibacterianos/efeitos adversos
Azitromicina/efeitos adversos
Bordetella pertussis/isolamento & purificação
Criança
Pré-Escolar
Tosse/epidemiologia
Estolato de Eritromicina/efeitos adversos
Feminino
Gastroenteropatias/induzido quimicamente
Seres Humanos
Lactente
Masculino
Nasofaringe/microbiologia
Cooperação do Paciente
Prevalência
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 83905-01-5 (Azithromycin); XRJ2P631HP (Erythromycin Estolate)
[Em] Mês de entrada:0409
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:040703
[St] Status:MEDLINE


  8 / 126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:14998559
[Au] Autor:Pari L; Murugan P
[Ad] Endereço:Department of Biochemistry, Faculty of Science, Annamalai University, Tamil Nadu, India. paribala@sancharnet.in
[Ti] Título:Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity.
[So] Source:Pharmacol Res;49(5):481-6, 2004 May.
[Is] ISSN:1043-6618
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Tetrahydrocurcumin (THC), one of the major metabolites of curcumin, was investigated for its possible hepatoprotective effect in Wistar rats against erythromycin estolate-induced toxicity. Oral administration of THC significantly prevented the occurrence of erythromycin estolate-induced liver damage. The increased level of serum enzymes (aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP)), bilirubin, cholesterol, triglycerides, phospholipids, free fatty acids and plasma thiobarbituric acid reactive substances (TBARS) and hydroperoxides observed in rats treated with erythromycin estolate were very much reduced in rats treated with THC and erythromycin estolate. This biochemical observation were supplemented by histopathological examination of liver section. Results of this study revealed that THC could afford a significant protection against erthromycin estolate-induced hepatocellular damage. Tetrahydrocurcumin had a better protective effect when compared with Silymarin, a reference drug.
[Mh] Termos MeSH primário: Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle
Curcumina/análogos & derivados
Curcumina/uso terapêutico
Estolato de Eritromicina/efeitos adversos
Estolato de Eritromicina/antagonistas & inibidores
[Mh] Termos MeSH secundário: Administração Oral
Alanina Transaminase/sangue
Alanina Transaminase/efeitos dos fármacos
Fosfatase Alcalina/sangue
Fosfatase Alcalina/efeitos dos fármacos
Animais
Aspartato Aminotransferases/sangue
Aspartato Aminotransferases/efeitos dos fármacos
Bilirrubina/sangue
Hidroxitolueno Butilado
Doença Hepática Induzida por Substâncias e Drogas/patologia
Colesterol/sangue
Curcumina/química
Curcumina/farmacologia
Estolato de Eritromicina/administração & dosagem
Ácidos Graxos não Esterificados/sangue
Feminino
Glutationa/sangue
Glutationa/efeitos dos fármacos
Glutationa/fisiologia
Peróxidos Lipídicos/sangue
Fosfolipídeos/sangue
Ratos
Ratos Wistar
Silimarina/administração & dosagem
Silimarina/efeitos adversos
Tiobarbitúricos/antagonistas & inibidores
Tiobarbitúricos/sangue
Triglicerídeos/sangue
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Fatty Acids, Nonesterified); 0 (Lipid Peroxides); 0 (Phospholipids); 0 (Silymarin); 0 (Thiobarbiturates); 0 (Triglycerides); 00U0645U03 (tetrahydrocurcumin); 1P9D0Z171K (Butylated Hydroxytoluene); 97C5T2UQ7J (Cholesterol); EC 2.6.1.1 (Aspartate Aminotransferases); EC 2.6.1.2 (Alanine Transaminase); EC 3.1.3.1 (Alkaline Phosphatase); GAN16C9B8O (Glutathione); IT942ZTH98 (Curcumin); RFM9X3LJ49 (Bilirubin); XRJ2P631HP (Erythromycin Estolate)
[Em] Mês de entrada:0505
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040305
[St] Status:MEDLINE


  9 / 126 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:14972610
[Au] Autor:Park SJ; Kim SH
[Ad] Endereço:Advanced Materials Division, Korea Research Institute of Chemical Technology, P.O. Box 107, Yusong, Taejon 305-600, South Korea. psjin@krict.re.kr
[Ti] Título:Preparation and characterization of biodegradable poly(l-lactide)/poly(ethylene glycol) microcapsules containing erythromycin by emulsion solvent evaporation technique.
[So] Source:J Colloid Interface Sci;271(2):336-41, 2004 Mar 15.
[Is] ISSN:0021-9797
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this work, the producing of a biodegradable poly(l-lactide) (PLA)/poly(ethylene glycol) (PEG) microcapsule by emulsion solvent evaporation method was investigated. The effect of PEG segments added to the PLA microcapsules on the degradation, size distribution, and release behavior was studied. According to the results, PLA/PEG copolymer was more hydrophilic than PLA homopolymer, and with lower glass transition temperature. The surface of PLA/PEG microcapsules was not as smooth as that of PLA microcapsules, the mean diameters of prepared PLA and PLA/PEG microcapsules were 40 and 57 microm, respectively. And spherical forms were observed by the image analyzer and the scanning electron microscope (SEM). Drug release from microcapsules was affected by the properties of PLA/PEG copolymers determined by UV-vis spectra. It was found that the drug release rates of the microcapsules were significantly increased with adding of PEG, which explained by increasing hydrophilic groups.
[Mh] Termos MeSH primário: Cápsulas/química
Composição de Medicamentos/métodos
Estolato de Eritromicina/química
Lactatos/química
Polietilenoglicóis/química
[Mh] Termos MeSH secundário: Materiais Biocompatíveis/síntese química
Materiais Biocompatíveis/química
Cápsulas/síntese química
Preparações de Ação Retardada/síntese química
Preparações de Ação Retardada/química
Portadores de Fármacos/síntese química
Portadores de Fármacos/química
Estabilidade de Medicamentos
Concentração de Íons de Hidrogênio
Processamento de Imagem Assistida por Computador
Lactatos/síntese química
Microscopia Eletrônica de Varredura
Estrutura Molecular
Peso Molecular
Tamanho da Partícula
Polietilenoglicóis/síntese química
Fatores de Tempo
Água/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biocompatible Materials); 0 (Capsules); 0 (Delayed-Action Preparations); 0 (Drug Carriers); 0 (Lactates); 0 (poly(lactic acid-ethylene glycol)); 059QF0KO0R (Water); 30IQX730WE (Polyethylene Glycols); XRJ2P631HP (Erythromycin Estolate)
[Em] Mês de entrada:0406
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:040220
[St] Status:MEDLINE


  10 / 126 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:14682193
[Au] Autor:Pari L; Uma A
[Ad] Endereço:Department of Biochemistry, Faculty of Science, Annamalai University, Annamalainagar-608 002, Tamilnadu, India. paribala@sancharnet.in
[Ti] Título:Protective effect of Sesbania grandiflora against erythromycin estolate-induced hepatotoxicity.
[So] Source:Therapie;58(5):439-43, 2003 Sep-Oct.
[Is] ISSN:0040-5957
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Sesbania grandiflora, commonly known as 'sesbania', is widely used in Indian folk medicine for the treatment of liver disorders. Oral administration of an ethanolic extract of S. grandiflora leaves (200 mg/kg/day) for 15 days produced significant hepatoprotection against erythromycin estolate (800 mg/kg/day)-induced hepatotoxicity in rats. The increased level of serum enzymes (aspartate transaminase, alanine transaminase, alkaline phosphatase), bilirubin, cholesterol, triglycerides, phospholipids, free fatty acids, plasma thiobarbituric acid reactive substances and hydroperoxides observed in rats treated with erythromycin estolate were significantly decreased in rats treated concomitantly with sesbania extract and erythromycin estolate. The sesbania extract also restored the depressed levels of antioxidants to near normal. The results of the study reveal that sesbania could afford a significant protective effect against erythromycin estolate-induced hepatotoxicity. The effect of sesbania was compared with that of silymarin, a reference hepatoprotective drug.
[Mh] Termos MeSH primário: Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle
Estolato de Eritromicina/toxicidade
Fitoterapia
Extratos Vegetais/uso terapêutico
Robinia
[Mh] Termos MeSH secundário: Administração Oral
Animais
Doença Hepática Induzida por Substâncias e Drogas/sangue
Avaliação Pré-Clínica de Medicamentos
Feminino
Depuradores de Radicais Livres/uso terapêutico
Hiperbilirrubinemia/induzido quimicamente
Hiperbilirrubinemia/prevenção & controle
Hiperlipidemias/induzido quimicamente
Hiperlipidemias/prevenção & controle
Peroxidação de Lipídeos/efeitos dos fármacos
Testes de Função Hepática
Estresse Oxidativo/efeitos dos fármacos
Extratos Vegetais/farmacologia
Folhas de Planta/química
Ratos
Ratos Wistar
Robinia/química
Silimarina/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Free Radical Scavengers); 0 (Plant Extracts); 0 (Silymarin); XRJ2P631HP (Erythromycin Estolate)
[Em] Mês de entrada:0404
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:031220
[St] Status:MEDLINE



página 1 de 13 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde